« Return to News | Ethics/Regulatory

BU professor fabricates data in two published experiments

Wednesday, August 10, 2011 11:43 AM

A cancer researcher and assistant professor at the Boston University School of Medicine Cancer Research Center fabricated data in two papers published in scientific journals, federal authorities announced, according to a report by the Boston Globe.

Sheng Wang, an assistant professor whose research involved molecular biology approaches to understanding cancer, no longer works at BU.  Wang has agreed to retract the two papers and will not be eligible for or involved in federally funded research for two years, according to the finding of research misconduct issued by the Office of Research Integrity of the US Department of Health and Human Services.

The federal authorities found that Wang engaged in research misconduct in projects supported by two federal grants from the National Cancer Institute. According to the federal finding, Wang fabricated experiments used in six out of seven figures in one paper and six out of eight figures in the other. He is listed as the senior author on both papers, which were published in 2009 and explored the role of a gene that suppresses tumor growth.

The sanctions described in the misconduct findings include Wang’s agreement to exclude himself from receiving funds or working for any US government agency for two years. He is also barred from serving on advisory or peer review committees, or as a consultant for the government’s Public Health Service.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.